A Phase II Single-Arm Study of Atezolizumab Monotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer: Clinical Evaluation of Novel Blood-Based Diagnostics
Latest Information Update: 01 Jun 2022
At a glance
- Drugs Atezolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Biomarker; Therapeutic Use
- Acronyms B-F1RST
- Sponsors Genentech
- 01 May 2022 Results published in the Nature Medicine
- 29 Jul 2019 Status changed from active, no longer recruiting to completed.
- 03 Apr 2019 Results of the exploratory subgroup analysis of atezolizumab clinical characteristics in patients with low circulating tumor DNA, presented at the 110th Annual Meeting of the American Association for Cancer Research